Creative Enzymes shows complete dedication to all enzyme-related solutions by providing stabilization and formulation services. We offer the whole package of services to address enzyme stability issues ranging from stabilization, stability tests, to formulation development. Our expertise will assure you that the developed products are of high efficacy, quality, and safety, regardless of the purity, identify,…
Vaccines are considered one of the most successful medical interventions in the past few centuries, aiming to harness the human immune system and generate lasting protection against specific diseases. Traditional vaccines rely on the use of inactivated pathogens to trigger an immune response. However, many of these formulations carry a high risk of causing allergies or…
The development of antibody-drug conjugates (ADCs) has progressed significantly over the past decade due to improvements in payloads, linkers, and conjugation methods. In particular, linker design plays a key role in regulating ADC stability in systemic circulation and payload release efficiency in tumors, thereby affecting ADC pharmacokinetics (PK), efficacy, and toxicity profiles. Some key parameters, such…
Bioorthogonal reactions are a series of chemical reactions that occur in biological environments with high yields, selectivity, efficiency, and no side reactions. These reactions include copper-catalyzed alkyne-azide cycloaddition (CuAAC), strain-promoted alkyne-azide cycloaddition, inverse electron demand Diels-Alder (IEDDA) reaction, and more. These bioorthogonal reactions find extensive applications in various fields, including radionuclide conjugate, metabolic engineering, drug…
Read More “Bioorthogonal Reactions in Radionuclide Conjugates” »
The FDA’s Center for Drug Evaluation and Research (CDER) regulatory approval of a total of 26 NME (New Molecular Entity) drugs in the first half of 2023. It is worth noting that the 26 drugs approved include 4 peptide drugs, accounting for 15% of the total. In the past 2022, the FDA has approved only…
Read More “FDA Approved Peptide Drugs in the First Half of 2023” »
In recent years, nucleic acid therapy involving various types of ribonucleic acids (RNAs), including messenger RNA (mRNA), small interfering RNA (siRNA), and microRNA (miRNA), has rapidly emerged as a new cornerstone of modern medicine. Among them, the mRNA-based vaccines developed, particularly the COVID-19 vaccine, have played a significant role in combating the novel coronavirus (SARS-CoV-2)…
Antibody-drug conjugates (ADCs) have revolutionized the field of targeted cancer therapy by combining the specificity of monoclonal antibodies with the potency of cytotoxic drugs. ADCs have shown remarkable clinical success, leading to several FDA-approved therapies. However, the development of the next generation of ADCs presents new strategies and challenges that must be addressed to improve efficacy,…
Read More “Strategies and Challenges for the Next Generation of Antibody-Drug Conjugates” »
Antibody-drug conjugates (ADCs), as emerging anticancer drugs, can deliver highly cytotoxic molecules directly to cancer cells to kill them. ADC is a monoclonal antibody covalently bound to cytotoxic chemical substances (payload) through linker. ADC linker plays a key role in the therapeutic effect of ADC, and its characteristics greatly affect the therapeutic index, pharmacodynamics and pharmacokinetics…
Read More “ADC Cleavable Linker: Classification and Mechanism of Action” »
Targeted therapies have significantly advanced the field of cancer therapy, and among these, antibody-drug conjugates (ADCs) have emerged as a viable therapeutic strategy. ADCs increase efficacy and decrease systemic toxicity by fusing the potency of cytotoxic drugs with the specificity of monoclonal antibodies (mAbs). The manufacture of high-quality and stable payloads by fermentation techniques is…
An unusual protein structure called a “corrugated beta sheet”, first predicted in 1953, has now been created in the laboratory and characterized in detail using X-ray crystallography. The new findings, published in Chemical Science in July, may enable the rational design of unique materials based on corrugated sheet-like structures. Jevgenij Raskatov, associate professor…
Read More “New Study Confirms ‘Ripple sheet’ Protein Structure Predicted in 1953” »
